(VIE) – Globe Newswire
-
Viela Bio Reports Fourth Quarter and Full Year 2020 Operating and Financial Results
-
Viela Bio Reports Fourth Quarter and Full Year 2020 Operating and Financial Results
-
Viela Bio Announces Additional Positive Results with UPLIZNA® (inebilizumab-cdon) in Patients with Neuromyelitis Optica Spectrum Disorder at the ACTRIMS 2021 Forum
-
Viela Bio Announces Additional Positive Results with UPLIZNA® (inebilizumab-cdon) in Patients with Neuromyelitis Optica Spectrum Disorder at the ACTRIMS 2021 Forum
-
INVESTIGATION ALERT: Halper Sadeh LLP Investigates MDCA, VIE, CLGX, CRHM; Shareholders Are Encouraged to Contact the Firm
-
Viela Bio to Report Fourth Quarter and Full Year 2020 Operating and Financial Results on March 1, 2021
-
Viela Bio to Report Fourth Quarter and Full Year 2020 Operating and Financial Results on March 1, 2021
-
VIELA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of VIE and Encourages Investors to Contact the Firm
-
Viela Bio Reports Third Quarter 2020 Financial Results and Program Highlights
-
Viela Bio Reports Third Quarter 2020 Financial Results and Program Highlights
-
Viela Bio Announces Final Results from Phase 1b Trial of VIB7734 in Patients with Cutaneous Lupus Erythematosus
-
Viela Bio Announces Final Results from Phase 1b Trial of VIB7734 in Patients with Cutaneous Lupus Erythematosus
-
Viela Bio to Webcast Third Quarter 2020 Financial Results and Program Highlights on November 10, 2020
-
Viela Bio to Webcast Third Quarter 2020 Financial Results and Program Highlights on November 10, 2020
-
Viela Bio Announces Data Presentations at the 8th Joint ACTRIMS-ECTRIMS Meeting, MS Virtual 2020
-
Viela Bio Announces Data Presentations at the 8th Joint ACTRIMS-ECTRIMS Meeting, MS Virtual 2020
-
Viela Bio Reports Second Quarter 2020 Financial Results and Program Highlights
-
Viela Bio Reports Second Quarter 2020 Financial Results and Program Highlights
-
Viela Bio to Webcast Second Quarter 2020 Financial Results and Program Highlights on August 12, 2020
-
Viela Bio to Webcast Second Quarter 2020 Financial Results and Program Highlights on August 12, 2020
-
Viela Bio Announces U.S. FDA Approval of UPLIZNA™ (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
-
Viela Bio Announces U.S. FDA Approval of UPLIZNA™ (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
-
Viela Bio Announces Pricing of Public Offering of Common Stock
-
Viela Bio Announces Pricing of Public Offering of Common Stock
-
Viela Bio Announces Proposed Public Offering of Common Stock
-
Viela Bio Announces Proposed Public Offering of Common Stock
-
Viela Bio Reports First Quarter 2020 Financial Results and Program Highlights
-
Viela Bio Reports First Quarter 2020 Financial Results and Program Highlights
-
Viela Bio Announces Positive Interim Results from a Phase 1b Study of VIB7734 in Patients with Cutaneous Lupus Erythematosus
-
Viela Bio Announces Positive Interim Results from a Phase 1b Study of VIB7734 in Patients with Cutaneous Lupus Erythematosus
-
Viela Bio to Webcast First Quarter 2020 Financial Results and Program Highlights on May 13, 2020
-
Viela Bio to Webcast First Quarter 2020 Financial Results and Program Highlights on May 13, 2020
-
Viela Bio Announces Election of Rachelle Jacques to its Board of Directors
-
Viela Bio Announces Election of Rachelle Jacques to its Board of Directors
-
Viela Bio Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights
-
Viela Bio Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights
-
Viela Bio to Webcast Fourth Quarter and Full Year 2019 Operating and Financial Results on March 25, 2020
-
Viela Bio to Webcast Fourth Quarter and Full Year 2019 Operating and Financial Results on March 25, 2020
-
Viela Bio Announces Initiation of Phase 2b Trial of VIB4920 in Sjögren’s Syndrome
-
Viela Bio Announces Initiation of Phase 2b Trial of VIB4920 in Sjögren’s Syndrome
-
Viela Bio Reports Third Quarter 2019 Financial Results and Business Highlights
-
Viela Bio Reports Third Quarter 2019 Financial Results and Business Highlights
-
Viela Bio Enters Strategic Collaboration with Mitsubishi Tanabe Pharma to Develop and Commercialize Inebilizumab for Autoimmune Diseases in Japan and Other Asia Regions
-
Viela Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Viela Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Viela Bio Announces Pricing of Initial Public Offering
Back to VIE Stock Lookup